BioArctic AB
F:B9A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
BioArctic AB (B9A) under the Base Case is 17.44 EUR per share.
Compared with the current market price of 26.26 EUR, the stock appears
Overvalued by 34% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What BioArctic AB Does
BioArctic is a Swedish drug company focused on treatments for neurodegenerative diseases, especially Alzheimer’s disease and Parkinson’s disease. It does not run a broad consumer business; instead, it discovers and develops medicines and then partners with larger pharmaceutical companies to test, manufacture, and sell them. Its best-known work is around antibody-based drugs that target harmful proteins in the brain.
- Headquarters
- Sweden SE
- Employees
- 49
- IPO date
- Oct 12, 2017
Balance Sheet
Continue B9A Research
Decided on BioArctic? Get an email when B9A reaches the price you’d buy at. Free with an account.
Other BioArctic listings
What is the Intrinsic Value of one B9A stock?
The intrinsic value for
BioArctic AB (B9A) under the Base Case is 17.44 EUR.
Is B9A stock undervalued or overvalued?
Compared with the current market price of 26.26 EUR, the stock appears Overvalued by 34% .